Abstract:Ji Won Park, 1, &ast Yoonki Hong, 2, &ast Chin Kook Rhee, 3 Hye Sook Choi, 4 Kyungjoo Kim, 3 Kwang Ha Yoo, 5 Ki-Suck Jung, 6 Joo Hun Park 1 1 Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, South Korea; 2 Department of Internal Medicine, Kangwon National University, Chuncheon, South Korea; 3 Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; 4 Department of Internal Medicine, Kyung Hee University Medical Center, Seoul, South Korea; 5 Department of Internal Medicine, Konkuk University School of Medicine, Seoul, South Korea; 6 Department of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Anyang, South Korea &astThese authors contributed equally to this work Correspondence: Joo Hun Park, Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Worldcup road 164, Suwon, Gyeonggi-do, 16499, South Korea, Tel +82-31-219-5116 ; +82-10-8379-8299, Fax +82-31-219-5124, Email ; Background: A comprehensive analysis of the effects of inhaled corticosteroids (ICS) on COPD in a real-world setting is required due to safety concerns regarding ICS in COPD. This study aimed to explore the impact of ICS on the prognosis of Asian COPD patients in the real-life world. Methods: We examined 978 COPD patients registered in the Korean National Health and Nutrition Examination Survey (KNHANES) database and with their data linked to Health Insurance and Review Assessment (HIRA) data. The outcome measures were ascertained by HIRA from January 1, 2009, to December 31, 2012. This study enrolled two arms; ICS users (N = 85, mean age = 66.7 ± 8.9 years) and non-ICS users (N = 893, mean age = 63.7 ± 9.7 years). Results: Compared to the non-ICS users, the ICS users had a higher rate of pneumonia, tuberculosis, and acute exacerbations ( P < 0.05). Hospitalization due to respiratory causes was also higher among ICS users ( P < 0.05). Multivariate analysis showed that acute exacerbation was independently associated with the development of pneumonia ( P < 0.05), whereas ICS therapy had a tendency to be associated with pneumonia. Another multivariate analysis demonstrated that old age, FEV 1 , ICS therapy, and pneumonia were independently associated with the occurrence of acute exacerbation ( P < 0.05). The concomitant pneumonia (HR = 3.353, P = 0.004) was independently associated with higher mortality ( P < 0.05). Conclusion: Our data demonstrated that the ICS users had a higher rate of pneumonia and tuberculosis and the concomitant pneumonia was independently associated with higher mortality, highlighting the importance of cautious and targeted administration of ICS in COPD. Keywords: COPD, inhaled corticosteroids, pneumonia, mortality Although chronic obstructive pulmonary disease (COPD) has been a major public health concern and was expected to rank third among all the causes of death by 2030, there is still no therapeutic intervention that modifies the natural course of COPD. 1,2 The pharmacological treatment of COPD comprises long-acting muscarinic antagonist (LAMA), long-acting beta-agonists (LABA), the combination of LAMA and LABA, the combination of LABA and inhaled corticosteroids (ICS), and triple therapy including LABA, LAMA, and ICS. The benefits of ICS in COPD reported by various studies include the reduction of frequency of COPD exacerbations, a lower rate of hospitalization, and a reduction of all-cause mortality in some COPD subgroups. 3–6 However, the use of ICS in COPD is much debated because of the associated safety concerns; 7–10 there is a concern about the attendant side effects of ICS on COPD including pneumonia and tuberculosis. 11,12 Consequently, the withdrawal of ICS in COPD patients is common due to ICS-related adverse events or treatment-related risks outweighing the expected benefits. 13,14 In addition, ICS treatment is associated with several challenges; observational studies suggested that overprescription of ICS is common in patients with COPD and smoking can result in steroid resistance by decreasing the efficacy of ICS in COPD. 13,15,16 However, so far, there are few comprehensive analyses of the effects of ICS on COPD in a real-world setting. Hence, this study was conducted to investigate the impact of ICS on the prognosis of Asian COPD patients in the real world setting by analyzing the Korean National Health and Nutrition -Abstract Truncated-

Blueprint for a stronger Food and Drug Administration.

The adherence to and utility of the Global Initiative for Chronic Obstructive Lung Disease guidelines for treating COPD among pulmonary specialists: a retrospective analysis

Genetic effects induced in Saccharomyces cerevisiae by cyclophosphamide in vitro without liver enzyme preparations.

COPD patients prescribed inhaled corticosteroid in primary care: time for re-assessment based on exacerbation rate and blood eosinophils?

Overuse of long-acting β2-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns

Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β2-agonist dual therapy in a primary care setting in England

A Cross-Sectional Study Assessing Appropriateness Of Inhaled Corticosteroid Treatment In Primary And Secondary Care Patients With COPD In Sweden

Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study

[Effects of drugs on preventing recurrent myocardial infarction in patients with healed myocardial infarction].

Healthcare Resource Utilization Associated with Intermittent Oral Corticosteroid Prescribing Patterns in Asthma

Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy

Rational use of inhaled corticosteroids for the treatment of COPD: a plain language summary

Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B2-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study

Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma

Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: a real-world study

The Impact of Inhaled Corticosteroids on the Prognosis of Chronic Obstructive Pulmonary Disease

Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma

The Use of Inhaled Corticosteroids for Patients with COPD Who Continue to Smoke Cigarettes: An Evaluation of Current Practice

Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History

Inhaled Corticosteroids Particle Size and Risk of Hospitalization Due to Exacerbations and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. A Nationwide Cohort Study

FURTHER OBSERVATIONS ON THE OVARIAN ASCORBIC ACID DEPLETION TESTS FOR LUTEINIZING HORMONE.